Literature DB >> 23056015

Association of paraoxonase activity and atherosclerosis in patients with chronic hepatitis B.

H Karsen1, I Binici, M Sunnetcioglu, A I Baran, M R Ceylan, S Selek, H Celik.   

Abstract

BACKGROUND: The hepatitis B virus is a significant pathogen that causes cirrhosis, and hepatocellular cancer as a result of the damage it causes to liver cells. Its infection affects more than 400 million people globally. Although there is an effective vaccine and treatment methods, almost 1, 000, 000 people die every year.
OBJECTIVE: To investigate paraoxonase and arylesterase activities along with oxidative status parameters and serum lipid levels, and to find out if there is any increased susceptibility to atherogenesis.
METHODS: Thirty-four subjects with chronic hepatitis B and 39 healthy subjects as control were enrolled in the study. Age, body mass index and gender, Serum Triglycerides (TG), High-density Lipoprotein (HDL) and Low-Density lipoprotein (LDL) levels, serum paraoxonase-1 and arylesterase activities were determined. Oxidative and antioxidative statuses were evaluated by measuring serum-free sulfhydryl groups, lipid hydroperoxide levels, total antioxidant capacity, total oxidant status, and oxidative stress index.
RESULTS: Serum TG and LDL levels were higher while serum HDL levels were lower in patients with chronic hepatitis B than in controls but the differences did not reach statistical significance. Serum paraoxonase-1 and arylesterase activities, plasma free sulfhydryl groups, and total antioxidant capacity were significantly lower in patients than in controls (p=0.018, p=0.005, p<0.001, p=0.037 respectively), while lipid hydroperoxide, total oxidant status, and oxidative stress index were significantly higher (for all p<0.001).
CONCLUSION: The diminution in the paraoxonase-1 and arylesterase activities could contribute to the accelerated development of atherosclerosis in patients with chronic hepatitis B.

Entities:  

Keywords:  Chronic hepatitis B; atherosclerosis; oxidative status; paraoxonase activity

Mesh:

Substances:

Year:  2012        PMID: 23056015      PMCID: PMC3462532          DOI: 10.4314/ahs.v12i2.6

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  20 in total

1.  Study of factors influencing the decreased HDL associated PON1 activity with aging.

Authors:  Ildiko Seres; Gyorgy Paragh; Elaine Deschene; Tamas Fulop; Abdelouahed Khalil
Journal:  Exp Gerontol       Date:  2004-01       Impact factor: 4.032

2.  A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation.

Authors:  Ozcan Erel
Journal:  Clin Biochem       Date:  2004-04       Impact factor: 3.281

3.  Chronic hepatitis B: update 2009.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

4.  A new automated colorimetric method for measuring total oxidant status.

Authors:  Ozcan Erel
Journal:  Clin Biochem       Date:  2005-10-07       Impact factor: 3.281

5.  The human serum paraoxonase/arylesterase polymorphism.

Authors:  H W Eckerson; C M Wyte; B N La Du
Journal:  Am J Hum Genet       Date:  1983-11       Impact factor: 11.025

6.  Paraoxonase gene polymorphisms and coronary reactivity in young healthy men.

Authors:  R Malin; J Knuuti; T Janatuinen; R Laaksonen; R Vesalainen; P Nuutila; H Jokela; J Laakso; O Jaakkola; T Solakivi; T Lehtimäki
Journal:  J Mol Med (Berl)       Date:  2001-08       Impact factor: 4.599

7.  Paraoxonase-1 activity modulates endothelial function in patients with peripheral arterial disease.

Authors:  Leonella Pasqualini; Claudio Cortese; Simona Marchesi; Donatella Siepi; Matteo Pirro; Gaetano Vaudo; Laura Liberatoscioli; Agostino Gnasso; Giuseppe Schillaci; Elmo Mannarino
Journal:  Atherosclerosis       Date:  2005-12       Impact factor: 5.162

8.  Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes.

Authors:  Mira Rosenblat; Rachel Karry; Michael Aviram
Journal:  Atherosclerosis       Date:  2005-10-17       Impact factor: 5.162

Review 9.  Pharmacogenetics of paraoxonases: a brief review.

Authors:  D I Draganov; B N La Du
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-25       Impact factor: 3.000

10.  Smoking-dependent association between paraoxonase 1 M/L55 genotype and coronary atherosclerosis in males: an autopsy study.

Authors:  Riikka Rontu; Pekka J Karhunen; Erkki Ilveskoski; Jussi Mikkelsson; Olli Kajander; Markus Perola; Antti Penttilä; Anna-Maija Koivisto; Terho Lehtimäki
Journal:  Atherosclerosis       Date:  2003-11       Impact factor: 5.162

View more
  6 in total

1.  Dr. Hasan Karsen replies.

Authors: 
Journal:  Afr Health Sci       Date:  2013-03       Impact factor: 0.927

2.  Evidence for association between paraoxonase-1 activity and diseases.

Authors: 
Journal:  Afr Health Sci       Date:  2013-03       Impact factor: 0.927

Review 3.  Hepatitis B and its Relationship With Oxidative Stress.

Authors:  Seyed Moayed Alavian; Alireza Showraki
Journal:  Hepat Mon       Date:  2016-07-17       Impact factor: 0.660

4.  Hepatitis B virus infection and decreased risk of stroke: a meta-analysis.

Authors:  Yaqin Wang; Jianping Xiong; Xi Chen; Meng Niu; Xiaowei Chen; Yuheng Guan; Kechuang Zheng; Ke Xu
Journal:  Oncotarget       Date:  2017-07-26

5.  Serum HBV surface antigen positivity is associated with low prevalence of metabolic syndrome: A meta-analysis.

Authors:  Yuanyuan Li; Ying Zhao; Jianping Wu
Journal:  PLoS One       Date:  2017-05-15       Impact factor: 3.240

6.  Contribution of Hepatitis B to Long-Term Outcome Among Patients With Acute Myocardial Infarction: A Nationwide Study.

Authors:  Pei-Lun Kuo; Kun-Chang Lin; Pei-Ling Tang; Chin-Chang Cheng; Wei-Chun Huang; Cheng-Hung Chiang; Hsiao-Chin Lin; Tzu-Jung Chuang; Shue-Ren Wann; Guang-Yuan Mar; Jin-Shiung Cheng; Chun-Peng Liu
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.